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Abstract
Background: B cells and antibodies are involved not only in controlling the spread of blood circulating Trypanosoma cruzi,
but also in the autoreactive manifestations observed in Chagas disease. Acute infection results in polyclonal B cell activation
associated with hypergammaglobulinemia, delayed specific humoral immunity and high levels of non-parasite specific
antibodies. Since TNF superfamily B lymphocyte Stimulator (BAFF) mediates polyclonal B cell response in vitro triggered by
T. cruzi antigens, and BAFF-Tg mice show similar signs to T. cruzi infected mice, we hypothesized that BAFF can mediate
polyclonal B cell response in experimental Chagas disease.
Methodology/Principal Findings: BAFF is produced early and persists throughout the infection. To analyze BAFF role in
experimental Chagas disease, Balb/c infected mice were injected with BR3:Fc, a soluble receptor of BAFF, to block BAFF
activity. By BAFF blockade we observed that this cytokine mediates the mature B cell response and the production of non-
parasite specific IgM and IgG. BAFF also influences the development of antinuclear IgG and parasite-specific IgM response,
not affecting T. cruzi-specific IgG and parasitemia. Interestingly, BAFF inhibition favors the parasitism in heart.
Conclusions/Significance: Our results demonstrate, for the first time, an active role for BAFF in shaping the mature B cell
repertoire in a parasite infection.
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Introduction
Chagas disease is a chronic disease caused by infection with
Trypanosoma cruzi. Initially, the disease goes through an acute
episode which is characterized by circulating parasites and
immunological disturbances that, at the level of B cell compart-
ment, are mature and immature B cell apoptosis [1,2] as well as
massive B cell response [3]. This polyclonal response [4–6], which
results in hipergammaglobulinemia [7] and delayed parasite
specific humoral response [8,9], may be the original cause for
the autoimmune phenomena that have been described in chronic
phases of infection [10,11]. It is well known that polyclonal
activation of B lymphocytes is invariably accompanied by
autoantibody production [12,13].
The polyclonal B cell activation that occurs during infection,
induced by the host response (T cell response, cytokines) or
parasite antigens, may disrupt normal immune regulatory
mechanisms and cause autoimmunity [14] It has been reported
that polyclonal B cell response in T. cruzi infected mice is
predominantly helper T-cell dependent [15]. However, Ig-
secreting plaque-forming cells are recorded in athymic (nude)
mice after T. cruzi infection [5] suggesting that T-independent
mechanisms can also mediate polyclonal B cell response. Several
parasite-encoded proteins have been identified as B cell mitogens
[13,16–18] and some of these T. cruzi antigens trigger in vitro
polyclonal B cell activation and differentiation in a T-independent
way [16,17]. We have reported that macrophages from normal
mice cultured with T. cruzi glutamate dehydrogenase, a T-
independent type II polyclonal B cell activator, secrete high level
of BAFF that mediates B cell polyclonal activation [17], suggesting
that BAFF may mediate the polyclonal B cell response in vivo
during T. cruzi infection.
BAFF is a crucial factor for the survival of peripheral B cells
[19–21]. But, in excess, BAFF leads to the development of
autoimmune disorders in animal models. It has been described
that BAFF transgenic mice show clear signs of B cell hyperplasia
and hyperglobulinemia. These mice have enlarged spleen, Peyer’s
patches and lymph nodes, circulating immune complexes,
rheumatoid factors, and anti-DNA Abs [22]. In addition, high
levels of BAFF have been detected in the serum of patients with
various autoimmune disorders [23,24]. Based on the fact that
BAFF transgenic and T. cruzi infected mice share many
immunological features like polyclonal activation, autoantibody
production and autoimmunity, we hypothesized that BAFF can
participate in the polyclonal B cell response observed in
experimental Chagas disease. In the present study, we quantified
www.plosntds.org 1 May 2010 | Volume 4 | Issue 5 | e679the levels of BAFF and analyzed the participation of BAFF on B
cell response by blocking its activity with a soluble BAFF-receptor
in T. cruzi infected mice.
Methods
Infection with T. cruzi and treatment with BR3:Fc or
control IgG2a
BALB/c mice were originally obtained from School of
Veterinary, La Plata National University (La Plata, Argentina)
and housed in our animal facility where all experiments were
performed in compliance with the Institutional Review Board and
Ethical Committee of the School of Chemical Sciences, National
University of Cordoba. BALB/c mice 6–8 wk old were intraper-
itoneally (i.p.) infected with 500 trypomastigotes from T. cruzi
(Tulahue ´n strain) diluted in physiological solution, as previously
described [2,25]. Non-infected normal littermates were injected
i.p. with physiological solution and processed in parallel. For
BAFF activity blocking, one day after infection, mice were injected
i.p. with 150 ug of BR3:Fc (Genentech Inc., South San Francisco,
CA, USA) three times per week. As control, infected mice were
injected with 150 ug of IgG2a or physiological solution. Non-
infected normal littermates were injected i.p. with physiological
solution and injected i.p. with 150 ug of BR3:Fc or 150 ug of
IgG2a or physiological solution with the same schedule described
above and processed in parallel. At 15 days after infection, mice
(number indicated in each figure) were killed by cervical
dislocation, blood was collected and lymphoid organs were
removed.
BR3:Fc efficacy of BAFF neutralization was tested in vivo
evaluating the reduction of splenic B cell subsets according to Lin
et al [26]. Also, BR3:Fc neutralizing BAFF activity was evaluated
in an in vitro assay measuring IgA concentration in the supernatant
of peritoneal B cells cultured with CpG plus recombinant BAFF
[27,28] in presence or in absence of BR3:Fc (data not shown).
Parasitemia counts
Blood was collected by retro-orbital bleeding, erythrocytes were
lysed in a 0.87% ammonium chloride buffer, and viable
trypomastigotes counted in a Neubauer counting chamber [2].
Cell preparation
Spleen and inguinal lymph nodes were obtained and homog-
enized through a tissue strainer. Peritoneal cells were obtained by
peritoneal washouts and bone marrow cells were isolated by
flushing femurs and tibias of mice with RPMI 1640. When it was
necessary, red blood cells were lysed for 5 min in Tris-ammonium
chloride buffer. Viable mononuclear cell numbers were deter-
mined by trypan blue exclusion using a Neubauer counting
chamber. Cell suspensions were processed for Flow cytometry
studies or culture as indicated below.
Purification of splenic cell population by cell sorting
To obtain B cells, T cells, dendritic cells and F 4/80
+
macrophages, splenic cells from infected mice were stained with
anti-B220 APC, anti-CD3 FITC, anti-CD11c PE, anti-F4/80
Biotin followed by Streptavidin Per-CP purchased from BD, and
sorted by positive selection with FACSAria Cell Sorter (Becton
Dickinson) to enrich populations to 98% for B and T cells and
88% for CD11c
+ and F 4/80
+.
Reverse transcription of mRNA and its relative
quantification by real time
Cells were incubated with TRIzol reagents (Life Technologies)
and RNA was extracted according to the manufacturer’s
recommendation and stored at 270uC. RNA was reverse
transcribed using Moloney murine leukemia virus reverse
transcriptase (Invitrogen, USA) at 42uC for 60 min. One
microgram of RNA was used to generate first cDNA strain. Real
Time PCR reactions for mouse BAFF and b-Actin detection
were performed using the following primers pairs: BAFF
(Mm00446347_m1, Applied Biosystems) and HPRT (HPRT-F:
59-AAGCTTGCTGGTGAAAAGGA-39; and HPRT R: 59-
TCCAACAAAGTCTGGCCTGT-39). The reaction mixtures
contained: TaqMan Universal PCR Master Mix in the case of
BAFF or 2X SYBR Green PCR Master Mix, 800 nM of HPRT
primers, and 50 ng of cDNA. All reactions were performed in
triplicate and were cycled as follows: 95uC for 10 min, 1 cycle;
95uC1 5s ,6 0 uC 1 min, 40 cycles; 95uC 15 s, 1 cycle, 60uC 1 min,
1 cycle, followed by a melting curve rising from 60 to 95uC
incrementally using in a 7500 System apparatus (Applied
Biosystems). HPRT was used as standard to normalize cDNA
loading [29].
Flow cytometry studies
Cell suspensions were washed twice in ice-cold FACS buffer
(Physiological solution with 2% fetal bovine serum (FBS, Gibco))
and preincubated with anti-mouse CD32/CD16 mAb (Fc block)
for 30 min at 4uC. The cells were then incubated with each PE-,
FITC-, or biotinylated Ab (e-Bioscience, San Diego, USA) for
30 min at 4uC and washed with FACS buffer: PE-anti B220,
FICT-anti IgM and biotin-anti IgD to identify mature B cells;
PE-anti CD138 and FICT-anti B220 to identify plasma cells; PE-
anti B220, FICT-anti CD24 and biotin anti IgD to identify
mature B cells in bone marrow, and biotin anti B220 to identify
peritoneal B cells. Data were acquired on a FACSCanto II
cytometer (Becton Dickinson) and analyzed using Flow Jo (Tree
Star) software.
Author Summary
Chagas disease, caused by the protozoan Trypanosoma
cruzi, is endemic in Central and South America. It affects 20
million people and about 100 million people are at risk of
infection in endemic areas. Some cases have been
identified in non-endemic countries as a consequence of
blood transfusion and organ transplantation. Chagas
disease presents three stages of infection. The acute phase
appears one to two weeks after infection and includes
fever, swelling around the bite site, enlarged lymph glands
and spleen, and fatigue. This stage is characterized by
circulating parasites and many immunological disturbanc-
es including a massive B cell response. In general, the
acute episode self-resolves in about 2 months and is
followed by a clinically silent indeterminate phase
characterized by absence of circulating parasites. In about
one-third of the cases, the indeterminate phase evolves
into a chronic phase with clinically defined cardiac or
digestive disturbances. Current knowledge suggests that
the persistence of parasites coupled with an unbalanced
immune response sustain inflammatory response in the
chronic stage. We believe that an effective treatment for
chronic Chagas disease should combine antiparasitic drugs
with immunomodulators aimed at reducing inflammation
and autoreactive response. Our findings enlighten a new
role of BAFF-BAFF-R signaling in parasite infection that
partially controls polyclonal B cell response but not
parasitespecific class-switched primary effectors B cells.
BAFF in T. cruzi Infection
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BAFF concentration (ng/ml) was determined in sera and culture
supernatant of mononuclear cells from lymphoid organs from
normal or T. cruzi infected mice by ELISA following manufactur-
er’s instructions (Axxora, USA).
Total immunoglobulin determination
Mononuclear cells from lymphoid organs from normal or T.
cruzi infected mice treated with physiological solution or BR3:Fc or
IgG2a control obtained at day 15 post infection (p.i.) were cultured
with media for 30 h. IgM and IgG concentrations (ng/ml) were
determined by ELISA as previously described [17]. In brief, plates
were coated with 2.5 ug/ml of the type-specific goat anti-mouse
Ab (IgM, IgG; Sigma-Aldrich Chemical Co) overnight at 4uC, and
blocked with 1% Bovine serum albumin (BSA). Culture superna-
tants were incubated overnight at 4uC. Peroxidase-conjugated
anti-mouse IgG or anti-mouse IgM (2.5 mg/ml) were added and
incubated for 1 h at 37uC. The reaction was developed with TMB
Substrate Reagent (BD OptEIA
TM). The concentration was
measured with reference to standard curves using known amounts
of the respective murine Ig (Sigma-Aldrich Chemical Co.).
Parasite specific serum Ab determination
The titers of T. cruzi specific seric IgM and IgG were
determined by ELISA [30,31] using T. cruzi trypomastigotes
recombinant Ags following manufacturer instruction (Wiener lab,
Argentina). ELISA test sera were considered positive if the mean
OD value was two standard deviations above the mean value for
control sera assayed in parallel.
ANA serum IgG determination
Amount of antinuclear specific IgG Ab (ng/ml) and IgG1,
IgG2a and IgG3 (OD) was determined by ELISA using a ANA
ELISA kit (Alpha Diagnostic, San Antonio, TX, USA) following
the manufacturer’s instructions in sera from T. cruzi infected mice
treated with physiological solution or BR3:Fc or IgG2a control.
Histopathology studies
Hearts were fixed in formaldehyde and embedded in paraffin
blocks, after which 5 to 20-mm-thick transverse sections were
mounted on slides and subsequently stained with hematoxylin and
eosin. Photographs were taken using a Nikon Eclipse TE 2000 U
equipped with a digital video camera. The grade of heart
parasitism was evaluated analyzing the number of nests containing
amastigotes per section.
Statistical analysis
Statistical significance of comparisons of mean values was
assessed by a two-tailed Student’s t test or nonparametric Mann-
Whitney U test using Graph pad software. In the case of T. cruzi
specific Abs, mean values was assessed by a one way non
parametric Kruskal-Wallis test. p#0.05 was considered significant.
Results
BAFF concentration increased as a consequence of T.
cruzi infection
To investigate systemic BAFF concentration during T. cruzi
infection, serum samples were collected at different times p.i. and
analyzed for levels of circulating BAFF by ELISA. During an
ongoing T. cruzi infection, a significant increase in the seric levels
of BAFF was detected at 11 days p.i. BAFF concentration
presented the highest value at the peak of parasitemia (day 11–15
p.i, [2]) and persisted elevated until the last day analyzed (day 32
p.i) (Fig 1A). Additionally, cells from the spleen and bone marrow,
but not from the lymph nodes and peritoneal cavity, obtained
from 15-day infected mice and cultured in the absence of stimuli,
released higher concentrations of BAFF than cells from non-
infected mice (Fig 1B).
To identify which mononuclear cells produced BAFF in T. cruzi
infected mice, CD3
+cells, CD11c
+cells, F4/80
+ cells and B220
+
cells were obtained by cell sorting from the spleen of infected mice.
By real-time PCR we determined that F4/80
+ cells and CD11c
+
cells showed high levels of mRNA coding for BAFF. The transcript
for BAFF was present at low levels in T cells and undetectable in B
cells. mRNA from total spleen cells from T. cruzi infected mice was
used as positive control (Fig 1C).
BAFF blockade resulted in a diminution of mature B cells
in lymphoid organs
In order to analyze the potential role of BAFF in the massive B
cell response in experimental Chagas disease, BAFF activity was
blocked by injecting BR3:Fc, a soluble BAFF receptor, into T. cruzi
infected mice. Considering that the different B cell compartments
are dissimilarly affected by T. cruzi infection [2,32,33], we
evaluated how the BAFF blockade affected each B cell
compartment individually.
We observed that treatment with BR3:Fc resulted in a
significant reduction of splenic and lymph nodes B220
+ cell
number in non-infected and in T. cruzi infected mice (Fig 2). We
determined that the reduction affected mature B220
+IgD
+IgM
+
spleen cells but did not induce significant changes in the number
of B220
+IgD
2IgM
+ spleen cells (phenotype compatible with
immature, marginal zone and activated B cell) (Fig S1 A). BAFF
inhibition reduced the already low number of B cells present in
the bone marrow of T. cruzi infected but did not affect the
number of B cells in the bone marrow of normal mice (Fig 2).
This result could be explained by the fact that BAFF blockade
affected mature B220
+ IgD
+CD24
+ but not immature B220
+
IgD
2 CD24
hi B cells from bone marrow (Fig S1 B). Immature B
cells are the major B cell population in the bone marrow of
normal mice but are almost absent in T. cruzi infected mice that
present only mature B cells [2]. In addition, we determined that
BAFF blockade did not change the number of peritoneal B220
+
cells observed in T. cruzi infected mice (Fig 2) that were reduced
as a consequence of infection [34]. Mice injected with control
isotype non-blocking Ab presented no significant difference in B
cell number in comparison to non-treated non infected (NI) or
infected (I) mice (Fig 2).
Next, we analyzed if B cell reduction observed in lymphoid
organs as a consequence of BAFF blockade also affected plasma
cell number. B220
+CD138
+ cell number declined markedly in the
spleen but remained unchanged in lymph nodes of BR3:Fc
treated-T. cruzi infected mice (Fig 3). T. cruzi infection per se
induced a severe reduction of plasma cell number in bone marrow
(Fig 3) and no further reduction was observed after BAFF
blockade.
BAFF inhibition partly impairs humoral immune response
in T. cruzi infected mice
The reduction of plasma cell number in T. cruzi infected mice
treated with BR3:Fc correlated with a significant reduction in IgM
and IgG concentration in culture supernatant of splenic cells
(Fig 4). Interestingly, while the concentration of IgG was
maintained, a reduction of IgM concentration was detected in
the culture supernatant of cells from peritoneum of T. cruzi
BAFF in T. cruzi Infection
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cell number results, no differences were detected in IgM and IgG
concentrations produced by cells from lymph nodes and bone
marrow from treated and untreated infected mice (Fig 4).
To analyze the biological significance of the reduced Ab
response observed in BR3:Fc treated T. cruzi infected mice, we
evaluated the levels of parasite specific Abs in sera. We observed
that preventing BAFF binding drastically diminished trypomasti-
Figure 1. BAFF production in T. cruzi infected mice. BAFF concentration (ng/ml) was determined by ELISA in: A, Sera from non-infected (day 0)
or T. cruzi infected mice obtained at different times of infection, B, culture supernatant of cells from spleen, bone marrow, lymph nodes and
peritoneal cavity from non-infected (NI) or T. cruzi infected (I) mice obtained at 15 days p.i. C, Splenic CD3
+, CD11c
+, F4/80
+ and B220
+ cells from T.
cruzi infected mice were purified by cell sorting. mRNAs were obtained from these populations from total splenic cells from I mice. Spleen cells from
NI and I mice were used as control. BAFF mRNA levels were quantified by Real Time PCR. The amounts of transcripts were normalized to HPRT
transcripts and were expressed relative to the amount in splenic cells from NI mice. Diamonds represent the value obtained from each mouse. The
lines represent the media value in each analyzed group. *, p#0.05. Results are representative for two individual experiments.
doi:10.1371/journal.pntd.0000679.g001
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did not change (Fig 5). Parasite-specific Abs were practically
undetectable in the culture supernatants of the lymphoid organs
obtained from infected mice indicating a low frequency of T. cruzi
antigen-specific B cells as reported [8,9] and a high frequency of
non-parasite specific Abs (data not shown).
To address the role of BAFF in the autoreactive humoral
response, we evaluated autoreactive Abs in the sera of treated and
control infected mice at 15 days p.i.. It has been described that
autoreactive Abs such as anti-actin, anti-myosin, anti-myoglobin
and antinuclear Abs (ANA) among others are present in the acute
and chronic phase of the pathology [35–37]. However, we were
unable to detect autoreactive Abs others than ANA at the acute
phase of the infection (day 15 p.i.). Therefore, ANA were tested as
markers of the effect of BR3:Fc treatment on the autoreactive B
cell population during acute phase of infection. We observed that
BAFF blockade prevented the production of ANA of IgG isotype
in T. cruzi infected mice. The isotype of IgG involved in this
reaction was IgG3 but not IgG2a or IgG1 (Fig 6).
BAFF inhibition influences parasite replication in the
heart
To analyze if B cell reduction and the decrease of IgM
parasite-specific Abs affected the parasite replication, we
measured the number of circulating trypomastigotes in blood of
infected mice and the grade of tissue parasitism by evaluating
amastigote niches in heart. Parasitemia was similar in T. cruzi
infected mice treated with physiological solution, BR3:Fc or
IgG2a control (Fig 7A), while cardiac parasitism was increased in
BR3:Fc treated infected mice in comparison to untreated infected
mice (Fig 7B,C). Thus, the hearts of infected mice in which BAFF
activity was blocked had higher number of nest of amastigotes in
the myocardial fibers of the auricle than non-treated infected
mice (Fig 7B,C).
Figure 2. B cell number in non-infected or T. cruzi infected mice treated with BR3:Fc. Cells from spleen, lymph nodes, bone marrow and
peritoneal cavity from non-infected (NI) or T. cruzi infected (day 15 p.i.) mice treated with physiological solution (I) or BR3:Fc (I+BR3:Fc) or IgG2a
control (I+IgG2a) were obtained, stained with anti-B220 and analyzed by flow cytometry. Graphs show the number of B220
+ cells in different
lymphoid compartments. Diamonds represent the value obtained from each mouse. The lines represent the media value.*, p#0.05. Results are
representative for three individual experiments.
doi:10.1371/journal.pntd.0000679.g002
BAFF in T. cruzi Infection
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Most of the information about BAFF in disease is linked to
autoimmune pathologies [38], but little information is available
about BAFF in infectious diseases [39,40]. Previously, we
reported that BAFF is involved in the polyclonal B cell
activation triggered in vitro by a T. cruzi antigen [17]. Here,
we extended these data showing that BAFF increased early in T.
cruzi infected mice and persisted at high levels throughout the
infection. Our data show that cells from immune system as
macrophages and dendritic cells which are susceptible to be
infected by T. cruzi and in which the parasite can replicate
intracellularly [41,42] are an important source of BAFF. It has
been reported that BAFF is mainly produced by innate immune
cells such as neutrophils, macrophages, monocytes, dendritic
cells (DCs) and follicular DCs [43] stimulated by cytokines often
produced during inflammation and infections [43,44], as well as
by the Toll-like receptors ligands [45]. Then, it is possible that
IL-10 and/or IFNc, which increase during infection [46–48], as
well as TLR ligands expressed by T. cruzi [49,50] or parasite
antigens [17] trigger BAFF secretion.
To analyze the role of BAFF in T. cruzi infection, infected mice
were treated with a soluble BAFF-R, BR3:Fc, to block BAFF
activity. The use of BAFF-R Fc considerably reduced mature
peripheral B cell numbers in T. cruzi infected mice. As it was
previously reported for normal mice [21,51,52], we observed that
mature B cells from T. cruzi infected mice have different BAFF
requirements than peritoneal mature B cells and/or immature B
cells for their survival. Reduction in mature B cells was also
observed in the bone marrow of infected mice, probably as a
consequence of the diminution of peripheral mature B cells.
Following B cell depletion, BAFF blockade resulted in a
reduction of splenic B220
+CD138
+ plasma cells. When we
analyzed the proportion of plasma cells with respect to the
number of total B cells we observed similar values in BR3:Fc
treated or untreated infected mice (data not shown). These results
suggest that during T. cruzi infection, BAFF apparently controls
plasma cell numbers by reducing the pool of mature B cells.
Concomitantly with plasma cell diminution, a reduction of total
IgM and IgG production by splenic cells was observed in BR3:Fc
treated infected mice. Since most of the Abs produced by splenic B
cells are non-parasite specific [8], our results suggest that BAFF is
regulating polyclonally activated B cells rather than antigen-
specific activated B cells. In agreement, parasite-specific IgG titers
were not affected by BAFF blockade while parasite-specific IgM
almost disappeared in BR3:Fc treated infected mice. Similar
behaviour was observed in three different independent experi-
ments analyzed at 15 and 22 days p.i. Our results confirm and
complete previously reported findings on the role of BAFF-BAFF-
R signalling in the survival and maintenance of the mature B cell
compartments [reviewed in 53], and that BAFF inhibition had a
markedly small effect on IgG
+ B cells and long-lived plasma cells.
Scholz et al [54] reported that IgM-bearing memory cells are
sensitive to BAFF depletion whereas IgG-bearing memory cells are
not.
Chagas disease pathology is associated to autoimmunity
[55–57]. There are several mechanisms to explain autoimmunity
induced by infectious agents [58]. All are based on the observation
that an immunocompetent host possesses circulating autoreactive
T and B cells that are normally tolerant to self antigens [59]. As a
Figure 3. Plasma cell number in non-infected or T. cruzi infected
mice treated with BR3:Fc. Cells from spleen, lymph nodes and bone
marrow from non-infected (NI) or T. cruzi infected (day 15 p.i.) mice
treated with physiological solution (I) or BR3:Fc (I+BR3:Fc) or IgG2a
control (I+IgG2a) were obtained, stained with anti-B220 and anti-CD138
and analyzed by flow cytometry. Graphs show the number of
B220
+CD138
+cells analyzed in each experimental group. Diamonds
represent the value obtained from each mouse. The lines represent the
media value in each condition.*, p#0.05. Results are representative for
three individual experiments.
doi:10.1371/journal.pntd.0000679.g003
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treated with physiological solution (I) or BR3:Fc (I+BR3:Fc) or IgG2a control (I+IgG2a) were obtained at day 15 p.i. and analyzed by ELISA to determine
T. cruzi specific IgM and IgG Ab titers. Diamonds represent the value obtained from each mouse. The lines represent the media value in each case. *,
p#0.05. Results are representative for two individual experiments.
doi:10.1371/journal.pntd.0000679.g005
Figure 4. Immunoglobulin concentration in T. cruzi infected mice treated with BR3:Fc. Cells from spleen, lymph nodes, bone marrow and
peritoneal cavity from T. cruzi infected (day 15 p.i.) mice treated with physiological solution (I) or BR3:Fc (I+BR3:Fc) or IgG2a control (I+IgG2a) were
obtained and cultured with media without any stimulus for 30 h. IgM and IgG concentration (ng/ml) was determined in culture supernatants by
ELISA. Diamonds represent the value obtained from each mouse. The lines represent the media value in each condition.*, p#0.05. Results are
representative for three individual experiments.
doi:10.1371/journal.pntd.0000679.g004
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induced by microorganisms, an unspecific activation may occur
[60]. Excess BAFF may lower the threshold for BCR signaling and
maintain survival when a normal autoreactive B cell would
undergo death [61]. In agreement with reports showing evidences
of BAFF participation in autoreactive response [62–67], BAFF
blockade decreases the ANA IgG in T. cruzi infected mice.
According to our results, it has been previously reported that a 4-
week course of BAFF-R–Ig prevents the emergence of IgG anti-
DNA antibodies in NZB/W mice [68].
The presence of anti-self antibodies was reported at the acute
and chronic phase of T. cruzi infection [35,37]. However, in our
infection model, probably as consequence of different experimen-
tal conditions and the parasite and mouse strain used, we were
unable to detect, by ELISA, anti-myosin, anti- myoglobin and
anti-skeletal muscle antibodies in sera of acutely-infected mice (day
15 p.i.). Consequently, we ignore whether BAFF blockade affects
the production of other autoreactive Abs different from ANA. Our
data analyzed together indicated that autoreactive IgG3
+ B cells
activated during the infection and the parasite specific IgG
+ B cells
induced by T. cruzi show a differential requirement of BAFF to
proliferate and/or differentiate and/or survive. This difference is
probably related to the nature of B cell response: T-independent,
extrafolicular or from germinal center [53]. Probably IgG3 ANA
are produced during a pre-germinal center response [69–71] while
anti-T. cruzi IgG Abs are produced in the course of a germinal
center response (Bermejo et al. unpublished observation).
Importantly, this differential requirement of BAFF may become
an important target of manipulation to control a possible
pathological autoreactive response without dampening the pro-
tective parasite specific response.
Interestingly, blocking BAFF is apparently not affecting the Abs
involved in the control of circulating trypomastigotes. It seems that
the conserved levels of IgG are sufficient to control parasite
replication, or that, other populations different from B cells and
not affected by BAFF inhibition, may be controlling parasite
spreading. However, BAFF blockade does impact in T. cruzi
replication in the heart, favoring the appearance of T. cruzi
pseudocyts. The increase in the parasite replication in target
tissues observed in BR3:Fc treated mice could be consequence of
the markedly reduced mature B cell numbers that affect not only
the production of Abs but also the development of protective
cellular responses [72]. Strikingly, in spite of the high number of T.
cruzi pseudocyts observed in the hearts of infected mice,
preliminary data showed that BR3:Fc treated mice survive longer
than non-treated infected mice (data not shown). Our findings
enlighten a new role of BAFF-BAFF-R signalling in a parasite
infection where it controls mature B cell numbers, polyclonal B
cell activation and self-reactive response but does not affect
protective anti-parasite IgG response.
Figure 6. Autoreactive immunoglobulins in sera from T. cruzi infected mice treated with BR3:Fc. Sera from T. cruzi infected mice treated
with physiological solution (I) or BR3:Fc (I+BR3:Fc) or IgG2a control (I+IgG2a) were obtained at day 15 p.i. and analyzed by ELISA to determine the
levels of antinuclear (ANA) specific IgG (ng/mL) or ANA IgG3, IgG1 and IgG2a (O. D.) Diamonds represent the value obtained from each mouse. The
lines represent the media value in each case. *, p#0.05. Results are representative for two individual experiments.
doi:10.1371/journal.pntd.0000679.g006
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www.plosntds.org 8 May 2010 | Volume 4 | Issue 5 | e679Figure 7. Circulating and tissue parasites in T. cruzi infected mice treated with BR3:Fc. A, Number of circulating parasites in blood samples
from T. cruzi infected mice treated with physiological solution (I) or BR3:Fc (I+BR3:Fc) or IgG2a control (I+IgG2a) was determined at days 15 p.i. by
counting in Neubauer chamber. B, Photomicrographs from heart sections obtained from T. cruzi infected mice treated with physiological solution (I)
or BR3:Fc (I+BR3:Fc) stained with hematoxilina/eosina (400X). Amastigote nests are demarcated with squares. Inset shows one of them (1000X). C,
Number of amastigote nests counted in 100 histological fields of hearts. Diamonds represent the value obtained from each mouse. The lines
represent the media value in each day p.i. Results are representative for two individual experiments.
doi:10.1371/journal.pntd.0000679.g007
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Figure S1 Immature and mature B cell number in non-infected
or T. cruzi infected mice treated with BR3:Fc. Cells from spleen
and bone marrow from non-infected (NI) or T. cruzi infected (day
15 p.i.) mice treated with physiological solution (I) or BR3:Fc
(I+BR3:Fc) or IgG2a control (I+IgG2a) were obtained. Cells from
spleen were stained with anti-B220, anti-IgD and anti-IgM, and
cells from bone marrow were stained with anti-B220, anti-IgD and
anti-CD24 and analyzed by flow cytometry. Graphs show the
number of: A) B220+ IgD+IgM+ (mature B cells) and B220+IgD-
IgM+ in spleen and B) B220+IgD+CD24+ (mature B cells) and
B220+IgD-CD24hi (immature B cells) in bone marrow. Diamonds
represent the value obtained from each mouse. The lines represent
the media value. *, p,0.05. Results are representative for three
individual experiments.
Found at: doi:10.1371/journal.pntd.0000679.s001 (0.58 MB TIF)
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